Schneider, Bryan P.Sledge Jr, George W.2021-01-292021-01-292009-05-18Schneider, B.P., Sledge, G.W. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?. Breast Cancer Res 11, 303 (2009). https://doi.org/10.1186/bcr2250https://hdl.handle.net/1805/25074Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?en-USAttribution 4.0 InternationalBevacizumabTrastuzumabSunitinibMicrometastatic DiseaseArticle